Evaluation of outcomes after discontinuing androgen suppression therapy in a series of elderly patients with advanced prostate cancer and in prolonged clinical and biochemical response

20504 Background: To describe and discuss the outcomes following the suspension of androgen suppression therapy (AST) in a series of elderly patients in advanced stage of prostate cancer and in established clinical and biochemical response after an extended period of treatment. Methods: A retrospective review of 371 consecutive patients with stage T3–4 NX- 1M0–1 prostate cancer and treated with single or combined androgen suppression therapy revealed 44 older patients who, after at least 36 months of treatment, showed the following findings of stable response (SR): absence of noteworthy dysuria, normal prostate findings on digital rectal examination (DRE), and prostate specific antigen (PSA) value lower than 0.50 ng/ml. Treatment was suspended in these patients, but was to be re-scheduled in one of the following cases: onset of important dysuria, evidence of palpable lesion on DRE, rise in PSA above 10 ng/ml or above pre-treatment values if these were below 10. Progression disease was defined as follows: ...